Table 2.

Characteristics of patients with MAC pulmonary disease following lung cancer treatment.

Case	Gender	Age	Pulmonary risk factors for NTM	Cancer diagnosis	Cancer type	Cancer treatment	MAC diagnosis	Method of diagnosis	Date of death (mon/day/year)
1	F	48	None	2000	ADCA	Radiation therapy and Chemotherapy	2011	Bronchoscopy	Living
2	F	74	COPD	2001 2008	Carcinoid ADCA	Surgery	2009	Bronchoscopy	Living
3	F	74	COPD/Bronchiectasis	2008	Squamous	Surgery	2011	+ Sputum Microbiology (×2)	Living
4	F	75	COPDa	2001	ADCA	Surgery and Radiation therapy	2005	BAL + Sputum Microbiology (×3)	Living
5	F	48	Noneb	2003	ADCA	Surgery, Radiation therapy and Chemotherapy	2012	BAL	12/7/2012
6	F	74	Bronchiectasis	2003 2014	Small cell Squamous	Radiation therapy and Chemotherapy	2011	BAL	05/31/2015
7	F	76	COPD	1977	ADCA	Surgery	2006	+ Sputum Microbiology (×2)	04/05/2011
8	F	75	COPD	1991	ADCA	Surgery	2012	+ Sputum Microbiology (×3) Lung tissue	Living
9	F	73	COPD	2006	Squamous	Radiation therapy and Chemotherapy	2009	Bronchial Washing	Living
10	M	82	None	2001	Carcinoid	Surgery	2007	Bronchoscopy	10/24/2009
11	M	82	None	2011	ADCA	Surgery	2014	Lung tissue	09/26/2015
12	M	78	None	2011	ADCA	Surgery and Chemotherapy	2015	BAL	Living
13	M	49	Bronchiectasisc	1997	Carcinoid	Surgery	2015	Outside + Microbiology	Living

Abbreviations: F = female; M = male; NTM=Non-tuberculous mycobacteria; MAC = Mycobacterium avium complex; ADCA = Adenocarcinoma; BAL= Bronchoalveolar lavage; COPD= Chronic obstructive pulmonary disease; N/A = Not available.

^aPatient was also previously treated with etanercept.

^bPatient was also treated with everolimus for metastatic renal cell carcinoma.

^cPatient was also diagnosed with lymphoma soon after the initial diagnosis of MAC pulmonary disease.